CoChat

EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins

Wels, Winfried, Beerli, Roger, Hellmann, Peter, Schmidt, Mathias, Marte, Barbara M., Kornilova, Elena S., Hekele, Armin, Mendelsohn, John, Groner, Bernd, Hynes, Nancy E. · 1995 · International Journal of Cancer
Cited by 97

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Many human tumors over‐express erbB‐2 and EGF receptors. The membrane localization of these receptor tyrosine kinases make them appropriate targets for directed tumor therapy. We have used recombinant DNA technology to produce single‐chain antibody exotoxin A (scFv‐ETA) fusion proteins which specifically bind the erbB‐2 and EGF receptors. The scFv portion is composed of the heavy‐ and light‐chain variable domains of monoclonal antibodies which recognize the extracellular portion of each receptor. We have previously described the anti‐tumor activity of the bacterially produced scFv(FRP5)‐ETA directed to the erbB‐2 receptor. In this paper we describe the characteristics of scFv(225)‐ETA, a protein which binds the EGF receptor. The bacterially produced recombinant protein binds to the receptor with high affinity and inhibits the in vitro growth of the EGF receptor over‐expressing tumor cell lines A431 and MDA‐MB468. Combination treatment with scFv‐(FRPS)‐ETA and scFv(225)‐ETA led to an additive inhibitory effect on the in vitro growth of A431 cells. SKBR3 cells expressing low levels of EGF receptor but high levels of p 185 erbB‐2 were not affected by scFv(225)‐ETA treatment but were sensitive to scFv(FRP5)‐ETA. Stimulation of SKBR3 cells and HCII RI#11 mouse mammary epithelial cells expressing the human erbB‐2 with EGF led to an increase in scFv(FRP5)‐ETA activity, showing that the EGF‐induced activation of erbB‐2 can potentiate the action of the erbB‐2‐directed toxin. Treatment of athymic nude mice with scFv(FRP5)‐ETA and the combination of both scFv‐ETA proteins led to the transient arrest of growth of established A431 tumors. scFv(22S)‐ETA treatment alone was the most effective, leading to tumor shrinkage during the course of treatment, whereas treatment with the parental monoclonal antibody 225 led to retarded tumor growth. © 1995 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.2910600120

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 97

Metadata

Authors
Wels, W., Beerli, R., Hellmann, P., Schmidt, M., Marte, B. M., Kornilova, E. S., Hekele, A., Mendelsohn, J., Groner, B., & Hynes, N. E.
Venue
International Journal of Cancer
Publisher
Wiley
Published
1995-01-03
Volume
60
Issue
1
Pages
137-144
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2002708378
Cited by
97
References
1
FWCI
3.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins. https://app.cochat.ai/papers/10.1002/ijc.2910600120
The paper
Wels, W., Beerli, R., Hellmann, P., Schmidt, M., Marte, B. M., Kornilova, E. S., Hekele, A., Mendelsohn, J., Groner, B., & Hynes, N. E. (1995). EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins. International Journal of Cancer. https://doi.org/10.1002/ijc.2910600120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.